Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C4H3F7O
CAS Number:
Molecular Weight:
200.05
UNSPSC Code:
41116107
NACRES:
NA.24
grade
pharmaceutical primary standard
API family
sevoflurane
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
FC(F)(F)C(OCF)C(F)(F)F
InChI
1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2
InChI key
DFEYYRMXOJXZRJ-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Sevoflurane EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under Sevoflurane
signalword
Warning
Storage Class
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
target_organs
Central nervous system
hcodes
Hazard Classifications
STOT SE 3
wgk
WGK 2
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Joachim Erb et al.
The Journal of international medical research, 42(3), 750-764 (2014-05-02)
Levosimendan is an inotropic drug with organ-protective properties due to its activation of mitochondrial K(ATP) channels. This prospective, randomized, double-blind, placebo-controlled study investigated whether administration of levosimendan prior to cardiopulmonary bypass could reduce organ dysfunction and influence subsequent secondary endpoints.
Norifumi Kuratani et al.
Anesthesiology, 109(2), 225-232 (2008-07-24)
Sevoflurane is a popular inhalational anesthetic for general anesthesia in children. The higher incidence of emergence agitation has been suspected after sevoflurane anesthesia as compared with halothane, whereas some controlled studies showed conflicting results. In this report, the authors performed
S Dahmani et al.
British journal of anaesthesia, 104(2), 216-223 (2010-01-06)
Emergence agitation (EA) in children is increased after sevoflurane anaesthesia. The efficacy of prophylactic treatment is controversial. The aim of this study was to provide a meta-analysis of the studies of the pharmacological prevention of EA in children. A comprehensive